SCHEMBL2674115

SCHEMBL2674115

CCc1cc(-c2noc(C)n2)c(C)nc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APOBEC3A P31941 1/20 0.47
▸ APOBEC3G Q9HC16 1/20 0.47
▸ HSD17B10 Q99714 6/20 0.45
▸ MAPT P10636 6/20 0.45
▸ KDM4E B2RXH2 4/20 0.45
▸ GAA P10253 2/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ RAB9A P51151 5/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ HPGD P15428 4/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ TSHR P16473 3/20 0.44
▸ LMNA P02545 5/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ ATM Q13315 1/20 0.43
▸ GABRA1 P14867 1/20 0.38
▸ GABRG2 P18507 1/20 0.38
▸ GABRB3 P28472 1/20 0.38
▸ GABRA5 P31644 1/20 0.38
▸ GABRA3 P34903 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2673207 0.79 APOBEC3A (0.37) APOBEC3AAPOBEC3GHSD17B10MAPTKDM4E
SCHEMBL2672881 0.77 APOBEC3A (0.38) APOBEC3AAPOBEC3GHSD17B10MAPTKDM4E
SCHEMBL2673093 0.74 APOBEC3A (0.33) APOBEC3AAPOBEC3G
SCHEMBL2672868 0.74 BRD4 (0.37) APOBEC3AAPOBEC3GMAPTKDM4ERAB9A
SCHEMBL2673810 0.74 HSD17B10 (0.40) APOBEC3AAPOBEC3GHSD17B10KDM4EALDH1A1
SCHEMBL2673740 0.73 APOBEC3A (0.37) APOBEC3AAPOBEC3GHSD17B10MAPTKDM4E
SCHEMBL2473556 0.73 S1PR1 (0.36) APOBEC3AAPOBEC3GHSD17B10KDM4ERAB9A
SCHEMBL1739907 0.73 S1PR1 (0.53) HSD17B10MAPTKDM4EGAANPSR1
SCHEMBL2476132 0.72 S1PR1 (0.35) APOBEC3AAPOBEC3GHSD17B10KDM4ERAB9A
SCHEMBL1741170 0.72 S1PR1 (0.67) HSD17B10MAPTKDM4EGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732896-B1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMA INC (US) 2012-12-12 — — EP disclosed
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-08-09 — — US disclosed
US-8173682-B2 Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-05-08 — — US disclosed
US-20070032489-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2007-02-08 — — US disclosed
EP-1732896-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) Aventis Pharmaceuticals Inc. (US) 2006-12-20 — — EP disclosed
WO-2005097750-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2005-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP2, PARP3 APOBEC3A 200/4885APOBEC3G 366/4885HSD17B10 1737/4885
US-20070032489-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP2, PARP3 APOBEC3A 200/4885APOBEC3G 366/4885HSD17B10 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback